相关实验视频

Updated: Jun 5, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

[新一代的CAR-T细胞]

Djamel Messaoudi¹, Franck Perez¹, Zélia Gouveia²

¹Dynamics of intracellular organization laboratory, Institut Curie, PSL Research University, Sorbonne Université, CNRS, UMR144, Paris, France.

Medecine sciences : M/S

|December 10, 2024

概括

化学抗原受体 (CAR) -T细胞治疗工程师的免疫细胞与癌症作斗争. 本综述详细介绍了CAR几代,从早期版本到先进的第五代疗法,解决了癌症治疗方面的挑战.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物技术是生物技术.

背景情况:

化学抗原受体 (CAR) -T细胞疗法代表了癌症免疫疗法的重大进展.
最近的成功已经导致FDA批准治疗血液性恶性瘤.

研究的目的:

提供关于CAR几代人的演变的全面概述.
讨论CAR T细胞治疗各种癌症和自身免疫性疾病的进展.

主要方法:

关于CAR T细胞疗法开发的科学文献的综述.
对不同CAR世代及其生物活动的分析.
讨论临床试验进展和局限性.

主要成果:

卡尔T细胞疗法经过五代人的发展,提高了疗效和安全性.
早期的CAR代表现出有限的细胞毒性活性,而后代的目标是克服持久性和毒性问题.
目前正在进行的试验探索CAR T细胞在固体瘤和自身免疫性疾病中的应用.

结论:

卡尔T细胞疗法是一个快速发展的领域,在瘤学中具有显著的潜力.
进一步的研究和开发对于解决局限性至关重要,特别是在固体瘤治疗方面.
CAR几代人的演变意味着向更有效,更安全的免疫疗法取得了进展.

更多相关视频

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.